Reach Us +447897072958
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal

Arto Urtti

Department of Pharmaceutical Biosciences, University of Helsinki, 00014 University of Helsinki, Finland


  • Opinion   
    Innovative Work of Chinese Enemy of Coronavirus Drugs
    Author(s): Arto Urtti*

    According to last update in several innovative Chinese antiviral drugs were under development or in use to combat the coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus. These drugs aimed to treat COVID-19 patients, reduce disease severity, and prevent severe complications. Some notable Chinese antiviral drugs and treatments included. Originally developed by Gilead Sciences, is an antiviral drug that showed promising results in clinical trials against SARS-CoV-2. The government approved its emergency use in COVID-19 patients, and several Chinese pharmaceutical companies were involved in the production of the drug. Favipiravir is another antiviral drug developed by a Japanese company, but it gained attention in China for its potential against COVID-19. Some Chinese pharmaceutical companies produced generic versions of the drug, making it widely available for COVID-19 trea.. Read More»
    DOI: 10.37421/2277-1506.2023.12.410

    Abstract HTML PDF